These novel Fora, in WEF-style format, will bring together corporate participants, neuroscientists and clinicians with outstanding experience in “hottest” research topics in the field of neurodegeneration to discuss the impact of newest preclinical results and cutting edge clinical findings on understanding and treatment development of neurodegenerative disorders. The objective is to exchange novel insights, challenges and solutions on the joint path forward to defining the future of Alzheimer’s and Parkinson’s therapeutics.
Each forum will be a moderated discussion with maximum 3 minutes introduction statement from each participant followed by questions from the audience. The forum is also open for journalists from different media, including lay press in and may report on progress made by the leaders in this field.
Forum Date & Title
Wednesday, March 6, 2024 | 14:30-15:30
BLOOD-BASED BIOMARKERS (BBM) – HOW DO THEY RELATE TO CSF, DIGITAL TOOLS, AND IMAGING BIOMARKERS?
Wednesday, March 6, 2024 | 15:35-16:35
IMMUNOTHERAPIES IN AD – WHAT ARE THE PRESENT CHALLENGES AND FUTURE BENEFITS?
Thursday, March 7, 2024 | 17:30-18:30
NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES
Friday, March 8, 2024 | 17:30-18:30
TRANSLATIONAL DRUG DEVELOPMENT IN AD (PHASE I-III) AND RELEVANCE FOR TREATMENT AND DISEASE MODIFICATION – WHAT COULD BE PROMISING STRATEGIES?
Saturday, March 9, 2024 | 15:30-16:30
ANTI-TAU THERAPIES IN CLINICAL TRIALS – WHAT ARE THE CHALLENGES AND OPPORTUNITIES FOR A RATIONAL THERAPY?
Saturday, March 9, 2024 | 17:00-18:00
THERAPY FOR AD, PD & LBD: MAJOR ETIOLOGICAL UNANSWERED QUESTIONS, MISSING TARGETS, AND FUNCTIONAL MARKERS
Saturday, March 9, 2024 | 18:05 – 19:05
DRUG DEVELOPMENT & BIOMARKERS IN RARE CNS DISEASES (ALS, FTD): FROM BASICS TOWARD APPROVAL – WHAT COULD BE PROMISING STRATEGIES?